Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.

Launched by HAYAT ABAD MEDICAL COMPLEX, PESHAWAR. · Jul 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying two different treatments for generalized vitiligo, a condition where large areas of the skin lose their color. The trial will compare how well and how safely a treatment called PUVA (which uses a combination of a light-sensitive medicine and ultraviolet A light) works compared to Tofacitinib, a medication taken as a pill. This research is important because vitiligo is common in Pakistan and can have a big emotional impact on those affected.

People who might be eligible to join are adults between 18 and 60 years old who have stable generalized vitiligo, meaning their skin condition has not changed or spread in the last three months and affects more than 10% of their body. Those with allergies to either treatment or who are pregnant or breastfeeding cannot participate, to keep everyone safe. If you join the study, you will receive one of the treatments, and doctors will monitor your skin’s response and watch for any side effects. This trial has not started recruiting yet, but it hopes to find out which treatment might be better for managing vitiligo.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Patients of either gender aged 18-60 years, diagnosed with generalized vitiligo (depigmentation affecting more than 10% of the body surface area).
• • Stable vitiligo (no new lesions or progression of existing lesions in the last three months).
• Exclusion Criteria:
• • Patients with a history of photosensitivity or allergies to Psoralen or Tofacitinib in order to prevent adverse reactions that could compromise patient safety and interfere with treatment efficacy assessment.
• • Pregnant or lactating women in order to ensure fetal and neonatal safety, as the effects of Psoralen and Tofacitinib on pregnancy and breastfeeding are not well studied and could pose potential risks.